Related Experiment Video

Updated: May 23, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

Connecting the Lines between Hypogonadism and Atherosclerosis

Akl C Fahed1, Joanna M Gholmieh, Sami T Azar

  • 1Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.

International Journal of Endocrinology
|April 21, 2012
PubMed

Insights

Aging males with hypogonadism face higher risks of atherosclerotic cardiovascular disease. This review clarifies the links between low testosterone, atherosclerosis, and related risk factors, offering clinical recommendations.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Gerontology

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) is a major global health concern, with older males at higher risk.
  • Hypogonadism, or low testosterone, is an underdiagnosed condition linked to ASCVD risk factors.
  • The relationship between testosterone levels and atherosclerosis is complex and not fully understood.

Purpose of the Study:

  • To review the evidence linking hypogonadism to atherosclerotic cardiovascular disease and its risk factors.
  • To elucidate the mechanistic pathways connecting testosterone deficiency to atherosclerosis.
  • To provide clinical guidance and identify future research needs.

Main Methods:

  • Comprehensive literature review of epidemiological studies.
  • Analysis of animal and laboratory experimental data.
  • Examination of clinical data from androgen deprivation therapy and testosterone-treated patients.

Main Results:

  • Epidemiological data indicate a higher incidence of ASCVD in aging males with hypogonadism.
  • Mechanistic studies suggest testosterone influences lipid metabolism, inflammation, and endothelial function, key in atherosclerosis.
  • Clinical studies show varied cardiovascular outcomes with testosterone therapy, underscoring the need for individualized treatment.

Conclusions:

  • Hypogonadism is a significant, often overlooked, risk factor for atherosclerotic cardiovascular disease in aging men.
  • Understanding the interplay between testosterone and cardiovascular health is crucial for effective prevention and management.
  • Further research is needed to optimize testosterone replacement therapy and its cardiovascular impact.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...